Clinical Trials
54
Active:5
Completed:9
Trial Phases
4 Phases
Early Phase 1:1
Phase 1:38
Phase 2:6
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (53 trials with phase data)• Click on a phase to view related trials
Phase 1
38 (71.7%)Phase 3
7 (13.2%)Phase 2
6 (11.3%)Early Phase 1
1 (1.9%)phase_1_2
1 (1.9%)APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1
Recruiting
- Conditions
- Platinum-resistant Recurrent Ovarian CancerAdvanced Solid Tumor
- Interventions
- Drug: APG -2449Drug: PLD
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06687070
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects with higher risk myelodysplastic syndrome (Higher Risk-MDS).
Phase 3
Not yet recruiting
- Conditions
- Newly Diagnosed Higher Risk Myelodysplastic Syndrome
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 203
- Registration Number
- 2024-517247-31-00
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇧🇪Algemeen Ziekenhuis Delta, Roeselare, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
A Study of Olverembatinib in SDH-deficient GIST.
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06640361
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of Olverembatinib (HQP1351) in Patients With CP-CML
Phase 3
Recruiting
- Conditions
- CMLChronic Myeloid LeukemiaCML, Chronic Phase
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 285
- Registration Number
- NCT06423911
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A study testing the new drug Lisaftoclax for newly diagnosed acute myeloid leukemia(GLORA-3)
Phase 3
Not yet recruiting
- Conditions
- Acute myeloid leukemia
- First Posted Date
- 2025-05-05
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 16
- Registration Number
- 2024-516436-10-00
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy
🇮🇹Humanitas Mirasole S.p.A., Rozzano, Italy
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
No news found